InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,228.12
(
0.22%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: DewDiligence post# 4660

Thursday, 07/31/2008 9:33:27 PM

Thursday, July 31, 2008 9:33:27 PM

Post# of 4764
<The prominent discussion of 11F8 on the recent CC and BMY’s buyout offer are not unrelated>. I tend to agree. However, I am still puzzled by the Adnexus purchase where BMY bought a competing technology to generate extracellular protein antagonists to receptor tyrosine kinases (the same RTKs that IMCL is working on). Given this purchase, do you think that there are any regulatory barriers/anti-trust issues in the BMY purchase of IMCL?

Regards,

biophud
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up